CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS)

References

• Feldman E, Goutman S, Petri S, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363–1380. doi: 10.1016/S0140-6736(22)01272-7
   PubMed Web of Science ®Google Scholar
• Arthur KC, Calvo A, Price TR, et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7(1). doi: 10.1038/ncomms12408
   Google Scholar
• Gladman M, Zinman L. The economic impact of amyotrophic lateral sclerosis: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):439–450. doi:10.1586/14737167.2015.1039941
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Factor-Litvak P, Andrews H, et al. ALS multicenter cohort study of oxidative stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3–4):192–203. doi: 10.3109/21678421.2013.864312
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–1226. doi: 10.1212/WNL.0b013e3181bc0141.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Motor neurone disease: assessment and management. London: National Institute for Health and Care Excellence (NICE);2019 Jul .
   Google Scholar
• Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020;192(46):E1453–68. doi: 10.1503/cmaj.191721.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996;347(9013):1425–1431. doi: 10.1016/S0140-6736(96)91680-3
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330(9):585–591. doi:10.1056/NEJM199403033300901
   PubMed Web of Science ®Google Scholar
• Vucic S, Lin CSY, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. 2013;136(Pt 5):1361–1370. doi: 10.1093/brain/awt085
   PubMed Web of Science ®Google Scholar
• Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512. doi: 10.1016/S1474-4422(17)30115-1
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Tsuji S, et al. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:11–19.
   PubMed Web of Science ®Google Scholar
• Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733–748. doi:10.1002/med.21528
   PubMed Web of Science ®Google Scholar
• Klavžar P, Koritnik B, Leonardis L, et al. Improvements in the multidisciplinary care are beneficial for survival in amyotrophic lateral sclerosis (ALS): experience from a tertiary ALS center. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3–4):203–208. doi: 10.1080/21678421.2020.1746809
   PubMed Web of Science ®Google Scholar
• Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;10(10). doi: 10.1002/14651858.CD004427.pub4
   PubMedGoogle Scholar
• Andrews JA, Jackson CE, Heiman-Patterson TD, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7–8):509–518. doi: 10.1080/21678421.2020.1771734
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416–422. doi: 10.1016/S1474-4422(18)30054-1
   PubMed Web of Science ®Google Scholar
• Shefner J, Heiman-Patterson T, Pioro EP, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of study 19 (MCI186-19). Muscle Nerve. 2020;61(2):218–221. doi: 10.1002/mus.26740
   PubMed Web of Science ®Google Scholar
• Lunetta C, Moglia C, Lizio A, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258–3267. doi: 10.1007/s00415-020-09993-z
   PubMed Web of Science ®Google Scholar
• Witzel S, Maier A, Steinbach R, et al. Safety and effectiveness of long-term intravenous Administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121–130. doi: 10.1001/jamaneurol.2021.4893
   PubMed Web of Science ®Google Scholar
• Jiang JS, Wang Y, Deng M. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front Pharmacol. 2022;13: doi: 10.3389/fphar.2022.1054006
   Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930. doi: 10.1056/NEJMoa1916945
   PubMed Web of Science ®Google Scholar
• Paganoni S, Hendrix S, Dickson SP, et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry. 2022;93(8):871–875. doi: 10.1136/jnnp-2022-329024
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099–1110. doi: 10.1056/NEJMoa2204705
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics. 2022;19(4):1248–1258. doi: 10.1007/s13311-022-01237-4
   PubMed Web of Science ®Google Scholar
• Paganoni S, Berry JD, Quintana M, et al. Adaptive Platform trials to transform amyotrophic lateral sclerosis therapy development. Ann Neurol. 2022;91(2):165–175. doi: 10.1002/ana.26285.
   PubMed Web of Science ®Google Scholar
• Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial) | Small Molecules | News Channels. [cited 2023 May 3]. Available from: https://pipelinereview.com/index.php/2022093081723/Small-Molecules/Biohaven-Provides-Update-From-Pivotal-Phase-2/3-Trial-with-Verdiperstat-in-Amyotrophic-Lateral-Sclerosis-Healy-ALS-Platform-Trial.html
   Google Scholar
• The HEALEY ALS Platform Trial completes enrollment for Regimen E evaluating SLS-005 (Trehalose) by Seelos Therapeutics. [cited 2023 May 3]. Available from: https://www.massgeneral.org/neurology/als/news/healey-center-regimen-e-2023
   Google Scholar
• Vucic S, Kiernan MC, Menon P, et al. Study protocol of RESCUE-ALS: a phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open. 2021;11(1):e041479. doi: 10.1136/bmjopen-2020-041479.
   PubMed Web of Science ®Google Scholar
• Robinson AP, Zhang JZ, Titus HE, et al. Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep. 2020;10(1). doi: 10.1038/s41598-020-58709-w
   Web of Science ®Google Scholar
• Harlan BA, Pehar M, Sharma DR, et al. Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1). J Biol Chem. 2016;291(20):10836–10846. doi: 10.1074/jbc.M115.698779
   PubMed Web of Science ®Google Scholar
• Kalmar B, Lu CH, Greensmith L. The role of heat shock proteins in amyotrophic lateral sclerosis: the therapeutic potential of arimoclomol. Pharmacol Ther. 2014;141(1):40–54. doi:10.1016/j.pharmthera.2013.08.003
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhu L, Qiu W, et al. Nicotinamide riboside enhances mitochondrial proteostasis and adult neurogenesis through activation of mitochondrial unfolded protein response signaling in the brain of ALS SOD1G93A mice. Int J Biol Sci. 2020;16(2):284–297. doi: 10.7150/ijbs.38487
   PubMed Web of Science ®Google Scholar
• Ho HS, Zhang JZ, Richard JP, et al. Redox-enhancing nanocatalysis improves motor neuron survival in vitro and SOD1 mouse motor function and survival in vivo. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(Supplement 1):239.
   Google Scholar
• CNM-Au8 Gold Nanocatalysis Protects Neurons Against Degeneration and Death in Multiple in vitro Models of Amyotrophic Lateral Sclerosis - MDA Clinical & Scientific Conference 2023. [cited 2023 May 3]. Available from: https://www.mdaconference.org/abstract-library/cnm-au8-gold-nanocatalysis-protects-neurons-against-degeneration-and-death-in-multiple-in-vitro-models-of-amyotrophic-lateral-sclerosis/
   Google Scholar
• Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13. doi: 10.3389/fnins.2019.01310.
   PubMed Web of Science ®Google Scholar
• Kanhai K, Zuiker R, Houghton W, et al. A first-in-human study in healthy subjects of the safety and pharmacokinetics of CNM-Au8, a suspension of catalytically active gold nanocrystals with remyelinating and neuroprotective properties. medRxiv. 2023. 05.11.23289871. doi: 10.1101/2023.05.11.23289871
   Google Scholar
• CNM-Au8 | ALZFORUM. [cited 2023 May 3]. Available from: https://www.alzforum.org/therapeutics/cnm-au8
   Google Scholar
• Vucic S, Menon P, Huynh W, et al. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension. EClinicalMedicine. 2023;60:102036.
   PubMedGoogle Scholar
• Neuwirth C, Barkhaus PE, Burkhardt C, et al. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the motor unit number index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry. 2015;86(11):1172–1179. doi: 10.1136/jnnp-2015-310509
   PubMed Web of Science ®Google Scholar
• Nandedkar SD, Barkhaus PE, Stålberg EV. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010;42(5):798–807. doi:10.1002/mus.21824
   PubMed Web of Science ®Google Scholar
• Clene Inc. Clene Nanomedicine announces top-line results from phase 2 RESCUE-ALS clinical trial. [cited 2023 May 3]. Available from: https://invest.clene.com/news-releases/news-release-details/clene-nanomedicine-announces-top-line-results-phase-2-rescue-als
   Google Scholar
• Vucic S, Menon P, Huynh W, et al. RESCUE-ALS trial results: a phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS. ENCALS Annual Meeting; Jun 1-3, 2022; Edinburgh, Scotland, UK.
   Google Scholar
• Vucic S, Menon P, Huynh W, et al. RESCUE-ALS trial results: a phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS. AANEM Annual Meeting; Sep 21-24, 2022; Nashville, TN, USA.
   Google Scholar
• Clene Inc. Clene reports topline results demonstrating survival signal for CNM-Au8® in healey ALS Platform trial. [cited 2023 May 3]. Available from: https://invest.clene.com/news-releases/news-release-details/clene-reports-topline-results-demonstrating-survival-signal-cnm.
   Google Scholar
• Clene Inc. CNM-Au8® associated with delayed time to key clinical progression events at six months supporting a survival benefit in the healey ALS Platform trial. [cited 2023 May 3]. Available from: https://invest.clene.com/news-releases/news-release-details/cnm-au8r-associated-delayed-time-key-clinical-progression-events
   Google Scholar